Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

• Main Authors: Liu, Jun, Tan, Cheryl Weiqi, Rigo, Frank, Ong, S. Tiong, Bhadra, Malini, Sinnakannu, Joanna Rajeswary, Yue, Wan Lin, Roca, Xavier
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2018
• Subjects: Alternative Splicing; BIM; DRNTU::Science::Biological sciences
• Online Access: https://hdl.handle.net/10356/87795; http://hdl.handle.net/10220/46816
• Institution: Nanyang Technological University

Many tyrosine kinase-driven cancers, including chronic myeloid leukemia (CML), are characterized by high response rates to specific tyrosine kinase inhibitors (TKIs) like imatinib. In East Asians, primary imatinib resistance is caused by a deletion polymorphism in Intron 2 of the BIM gene, whose pro...